101 related articles for article (PubMed ID: 37341420)
21. Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure.
Steve Tsang CC; Browning J; Todor L; Dougherty S; Hohmeier KC; Sam Li M; Borja-Hart N; Hines LE; Wang J
J Manag Care Spec Pharm; 2021 Aug; 27(8):971-981. PubMed ID: 34337985
[No Abstract] [Full Text] [Related]
22. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
23. A simple change to the Medicare Part D low-income subsidy program could save $5 billion.
Zhang Y; Zhou C; Baik SH
Health Aff (Millwood); 2014 Jun; 33(6):940-5. PubMed ID: 24889942
[TBL] [Abstract][Full Text] [Related]
24. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy.
Priest J; Buikema A; Engel-Nitz NM; Cook CL; Cantrell CR
Popul Health Manag; 2012 Apr; 15(2):101-12. PubMed ID: 22313439
[TBL] [Abstract][Full Text] [Related]
25. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
[TBL] [Abstract][Full Text] [Related]
26. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
27. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions.
Dusetzina SB; Huskamp HA; Rothman RL; Pinheiro LC; Roberts AW; Shah ND; Walunas TL; Wood WA; Zuckerman AD; Zullig LL; Keating NL
Health Aff (Millwood); 2022 Apr; 41(4):487-496. PubMed ID: 35377748
[TBL] [Abstract][Full Text] [Related]
28. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
29. Medicare Part D: Are Insurers Gaming the Low Income Subsidy Design?
Decarolis F
Am Econ Rev; 2015 Apr; 105(4):1547-80. PubMed ID: 29542882
[TBL] [Abstract][Full Text] [Related]
30. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
31. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
32. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
33. Use of intelligent assignment to Medicare Part D plans for people with schizophrenia could produce substantial savings.
Zhang Y; Baik SH; Newhouse JP
Health Aff (Millwood); 2015 Mar; 34(3):455-60. PubMed ID: 25732496
[TBL] [Abstract][Full Text] [Related]
34. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
[TBL] [Abstract][Full Text] [Related]
35. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
36. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
37. Awareness of the Medicare Part D Low-Income Subsidy among Older non-Hispanic Blacks and Hispanics.
Bakk L; Cadet TJ
Soc Work Public Health; 2018; 33(4):250-258. PubMed ID: 29694273
[TBL] [Abstract][Full Text] [Related]
38. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
39. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
[TBL] [Abstract][Full Text] [Related]
40. Participation of older patients with prostate cancer in Medicare eligible trials.
Craig BM; Gilbert SM; Herndon JB; Vogel B; Quinn GP
J Urol; 2010 Sep; 184(3):901-6. PubMed ID: 20643449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
